Clinical Trial

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK

Study acronym: DAYBREAK
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants with Neovascular (Wet) Age-related Macular Degeneration (wAMD)
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2024-08-13; most recent amendment 2026-04-23.
Status change: Recruiting → Active, Not Recruiting 2025-10-23
Trial Details
NCT Number NCT06556368
Lead Sponsor Kodiak Sciences Inc
Conditions Wet Age-related Macular Degeneration
Enrollment 675 participants
Start Date 2024-08-23
Primary Completion 2026-08 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2026-04-29